LIPOSARCOMA, DEDIFFERENTIATED
Clinical trials for LIPOSARCOMA, DEDIFFERENTIATED explained in plain language.
Never miss a new study
Get alerted when new LIPOSARCOMA, DEDIFFERENTIATED trials appear
Sign up with your email to follow new studies for LIPOSARCOMA, DEDIFFERENTIATED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cancer pill shows promise against rare, aggressive fat tissue tumors
Disease control CompletedThis completed Phase 3 trial tested whether a new oral medication called brigimadlin helps control advanced dedifferentiated liposarcoma, a rare and aggressive cancer of fat tissue. The study involved 138 adults with this cancer who took brigimadlin tablets once every three weeks…
Matched conditions: LIPOSARCOMA, DEDIFFERENTIATED
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Scientists test drug duo to control Tough-to-Treat fat tissue cancers
Disease control CompletedThis study tested whether adding a diabetes drug (pioglitazone) to a standard chemotherapy (trabectedin) could better control advanced liposarcoma, a rare cancer of fat tissue. It involved patients whose cancer had stopped responding to the standard drug alone. The goal was to se…
Matched conditions: LIPOSARCOMA, DEDIFFERENTIATED
Phase: PHASE2 • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New pill challenges chemo for rare cancer
Disease control CompletedThis study tested whether a new oral medication called brigimadlin could work better than standard chemotherapy (doxorubicin) for people with advanced dedifferentiated liposarcoma, a rare and aggressive cancer. 400 adults who hadn't received prior treatment for this cancer were r…
Matched conditions: LIPOSARCOMA, DEDIFFERENTIATED
Phase: PHASE2, PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC